Adrenomedullin and cardiovascular diseases
Open accessAbstract
The cardiovascular system is regulated by the autonomic nervous system, the renin-angiotensin-aldosterone system, nitric oxide (NO) and other factors including neuropeptides. Research in neurohumoral factors has led to the development of many cardiovascular drugs. Adrenomedullin (ADM), initially isolated from the adrenal gland, has diverse physiological and pathophysiological functions in the cardiovascular system. It is produced in many organs and tissues including the vasculature. ADM has numerous actions, including vasodilation, natriuresis, antiapoptosis and stimulation of NO production. It might play a protective role in various cardiovascular pathologies, and its plasma level is elevated in patients with hypertension and heart failure. Administration of ADM is a possible therapeutic approach for treating cardiovascular diseases. A number of studies have investigated the infusion of ADM in humans, which seems to be benficial in heart failure and myocardial infarction. Instead of ADM infusion, augmentation of its endogenous level is another possible strategy. Gene therapy is feasible in animal models, but its application in humans is limited. At present, the most promising clinical application of ADM is the use of the plasma level of mid-regional proadrenomedullin as a biomarker in cardiovascular diseases. It is a good marker of prognosis and survival in patients with coronary aretery disease or heart failure.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
ADM secretion is induced by inflammation, hypoxia and insulin resistance, and CVD and type 2 diabetes are linked to increased ADM levels.
“Secretion of ADM is induced in response to inflammation, hypoxia and insulin resistance such that CVD and type 2 diabetes (T2D) are linked to increased levels of ADM (4, 5).”
From Effect of liraglutide on atrial natriuretic peptide, adrenomedullin, and copeptin in PCOS (2018) · cites this paper as [5]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Identification of novel adrenomedullin in mammals: a potent cardiovascular and renal regulator
Takei, Y., Inoue, K., Ogoshi, M., Kawahara, T., Bannai, H., & Miyano, S. (2004) · FEBS Letters · doi:10.1016/s0014-5793(03)01368-1 · Cited by 268 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
DNA methylation GrimAge strongly predicts lifespan and healthspan
Lu, A. T., Quach, A., Wilson, J. G., Reiner, A. P., Aviv, A., Raj, K., Hou, L., Baccarelli, A. A., Li, Y., Stewart, J. D., et al. (2019) · Aging · doi:10.18632/aging.101684 · Cited by 2,540 · see citing works
Wong, H. K. (2014) · World Journal of Diabetes · doi:10.4239/wjd.v5.i3.364 · Cited by 51 · see citing works
Self-citationEffect of liraglutide on atrial natriuretic peptide, adrenomedullin, and copeptin in PCOS
Frøssing, S., Nylander, M., Kistorp, C., Skouby, S. O., & Faber, J. (2018) · Endocrine Connections · doi:10.1530/ec-17-0327 · Cited by 38 · see citing works
- Authors
- Wong, H. K., Cheung, T. T., & Cheung, B. M. Y.
- Affiliations
- University of Hong Kong (HK)
- Corresponding author
- Cheung, Bernard M Y
- Venue
- JRSM Cardiovascular Disease
- Publisher
- SAGE Publications
- Published
- 2012-08
- Volume
- 1
- Issue
- 5
- Pages
- 1-7
- ISSN
- 2048-0040 (ISSN-L)
- PMC
- PMC3738363
- OpenAlex
- W2101714206
- Cited by
- 106
- References
- 1
- Citations by year
- 2026: 3 · 2025: 10 · 2024: 10 · 2023: 16 · 2022: 7 · 2021: 11 · 2020: 11 · 2019: 3 · 2018: 9 · 2017: 6 · 2016: 9 · 2015: 4 · 2014: 6 · 2013: 1
- FWCI
- 0.37
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- JRSM Cardiovascular Disease (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuropeptides and Animal Physiology
- Health Sciences › Medicine › Surgery › Cardiovascular, Neuropeptides, and Oxidative Stress Research
- Health Sciences › Medicine › Pharmacology › Apelin-related biomedical research
- Keywords
- adrenomedullin, cardiovascular disease, heart failure, myocardial infarction, hypertension, vasodilation, nitric oxide, sodium excretion, apoptosis inhibition, mid-regional pro-adrenomedullin, biomarkers, gene therapy, coronary artery disease, prognosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
